Anisotropine

Summary

Anisotropine (CHEMBL1186610) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 282.4 Da · C17H32NO2+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1186610
Name	Anisotropine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	657202
Molecular formula	C17H32NO2+
Molecular weight	282.4
InChIKey	XGGHHHBGPSNXFE-XYPWUTKMSA-N

SMILES: CCCC(CCC)C(=O)OC1C[C@H]2CC[C@@H](C1)[N+]2(C)C

IUPAC name: [(1R,5S)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl] 2-propylpentanoate

Also known as: Octatropine, SID50103910, SID50103911, OCTATROPINE METHYLBROMIDE, octatropine methylbromide

Parent form; salt/anhydrous children: CHEMBL1578

Patent coverage: 343 distinct patent families (473 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Neuronal acetylcholine receptor subunit alpha-4, 5-hydroxytryptamine receptor 3A, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Alpha-1A adrenergic receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM3	7.44	AC50	36	nM	CHEMBL_ACT_25136937
CHRM1	6.77	AC50	170	nM	CHEMBL_ACT_25135717
CHRM2	6.2	AC50	630	nM	CHEMBL_ACT_25213981
KCNH2	5.68	AC50	2100	nM	CHEMBL_ACT_25118234

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).